ViMRT
}  
 
Home   
< Docs   

 IV mutation literature information.


  Identification of a Permissive Secondary Mutation That Restores the Enzymatic Activity of Oseltamivir Resistance Mutation H275Y.
 PMID: 35045267       2022       Journal of virology
Abstract: Here, we identified a new helper mutation, Y276F, that can rescue the functional defects of H275Y and contribute to the evolution of drug resistance in IAV.
Abstract: In this study, we measured the relative fitness, NA activity, and surface expression, as well as sensitivity to oseltamivir, for several oseltamivir resistance mutations, including H275Y in the wild-type and Y276F genetic background.
Abstract: Our results demonstrate that Y276F selectively rescues the fitness defect of H275Y by restoring its NA surface expression and enzymatic activity, elucidating the local compensatory structural impacts of Y276F on the adjacent H2


  Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
 PMID: 33540229       2021       European journal of medicinal chemistry
Abstract: In addition, D41 showed low toxicity and greater potency than reference compounds Oseltamivir and Amantadine against N1-H275Y variant in cellular assays.


  Inhibitory Activity of Honeysuckle Extracts against Influenza A Virus In Vitro and In Vivo.
 PMID: 33044658       2021       Virologica Sinica
Abstract: The acids-flavonoids mixture had the strongest inhibitory effects in vitro with EC50 values of 3.8, 4.1, and > 20 mug/mL against H1N1, H3N2 and H1N1-H275Y, respectively, showing competitive antiviral activity with oseltamivir and ribavirin.
Abstract: The cytopathic effect reduction assay showed that all the four extracts inhibited the replication of influenza viruses H1N1, H3N2 and the oseltamivir-resistant mutant strain H1N1-H275Y.


  Investigation of genetic variation: Neuraminidase gene of influenza A virus H1N1/pdm09, Shiraz, Iran (2015-2016).
 PMID: 33605468       2021       Journal of medical virology
Abstract: Based on sequencing results, 2 of the 44 sequenced isolates exhibited H275Y substitution, which presented oseltamivir resistance.


  Secondary substitutions in the hemagglutinin and neuraminidase genes associated with neuraminidase inhibitor resistance are rare in the Influenza Resistance Information Study (IRIS).
 PMID: 33713731       2021       Antiviral research
Abstract: All cultured viruses with the known resistance substitutions H275Y or R292K showed reduced susceptibility to oseltamivir in the NA-star assay.
Abstract: Known resistance substitutions were detected by mutation specific RT-PCR in viruses of 57 of 1803 (3.2%) oseltamivir-treated individuals, including 39 individuals infected with A/H1N1pdm09 [H275Y] virus and 18 with A/H3N2 [R292K] virus.
Abstract: Only in two A/H1N1pdm09 [H275Y] viruses, the potentially compensatory secondary substitutions HA-D52N and NA-R152K were detected.


  Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season.
 PMID: 34240696       2021       Euro surveillance
Result: Other drug resistance mutations, such as H275Y in the NA protein associated with oseltamivir resistance, were not present in our dataset.


  Development of 6E3 antibody-mediated SERS immunoassay for drug-resistant influenza virus.
 PMID: 34020222       2021       Biosensors & bioelectronics
Abstract: Furthermore, it was immobilized on Au nanoplate and nanoparticles, enabling surface-enhanced Raman scattering (SERS)-based detection of the H275Y mutant pH1N1.
Abstract: Here we report a novel 6E3 monoclonal antibody capable of recognizing and binding to the H275Y neuraminidase (NA) mutation, which has been associated with reduced susceptibility of influenza viruses to NA inhibitors.
Abstract: Molecular modeling studies also suggest the high-affinity binding of this antibody to pH1N1 H275Y NA.


  Genetic and antigenic characterization of influenza A/H5N1 viruses isolated from patients in Indonesia, 2008-2015.
 PMID: 32483655       2020       Virus genes
Result: However, none of the newly isolated viruses encoded known NAI resistance mutations (i.e., V116A, I117V, E119V, G136K, V149A, R156K, D198N, S246N, H275Y, R293K, N295S (N1 numbering)).


  Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir.
 PMID: 32449254       2020       Transplant infectious disease
Abstract: RESULTS: Two patients were infected with influenza A/H1pdm09 carrying a neuraminidase variant (H275Y) linked to oseltamivir resistance.


  Epidemic of influenza A(H1N1)pdm09 analyzed by full genome sequences and the first case of oseltamivir-resistant strain in Myanmar 2017.
 PMID: 32130243       2020       PloS one
Result: H275Y mutation on neuraminidase was found in one A(H1N1)pdm09 strain (A/Myanmar/17M307/2017), which was from an out-patient with no prior history of anti-viral treatment.
Result: All the other A(H1N1)pdm09 isolates from Yangon and Pyinmana study sites did not show H275Y mutation in NA (Table 4).
Result: In vitro fluorescence-based NAI assay performed on the selected influenza A(H1N1)pdm09 isolates (12 isolates from out-patients and 12 from in-patients) revealed that the H275Y mutant A(H1N1)pdm09 virus has elevated IC50 value for oseltamivir (301.5 nM with 198-fold increase) and peramivir (21.9 nM with 274-fold increase) but not for zanamivir (0.58 nM with 0.9-fold difference) and laninamivir (0.72 nM with 2.7-fold difference), when compared to the IC50 value of the



Browser Board

 Co-occurred Entities




   Filtrator